Catalent is the global leader in enabling pharmaceutical, biotechnology, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients globally.
With broad scale and deep expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Each year, Catalent helps accelerate over 1,500 partner programs, launches more than 150 new products, and supplies around 80 billion doses of nearly 8,000 products. Catalent’s global network comprises over 50 sites and an expert workforce of approximately 19,000, including over 3,000 scientists and technicians.
Catalent applies rigorous science, superior technologies, and deep expertise to improve its partners’ treatments and bring them through the clinic to patients, faster. Proactive investment and powerful partnerships help transform challenging molecules and new modalities into real treatments.
Catalent offers integrated development and product supply solutions that can be combined or tailored to enable customers to progress drugs, biologics, and consumer health products from laboratory to market, faster. Post-launch, Catalent provides comprehensive, integrated product supply, from sourcing bulk APIs through to manufacturing and packaging, release testing, and distribution. These flexible, scalable, and creative solutions meet the unique needs of partners of all sizes, from the smallest innovators to the largest pharmaceutical leaders and consumer health companies, advancing thousands of molecules through development towards commercial supply.
Headquartered in Somerset, NJ, the company generated nearly $5 billion in revenue in its 2022 fiscal year.
More products. Better treatments. Reliably supplied.TM
Posted Date: 11/30/2022
This record has been viewed 997 times.